Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 15/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.35 |
| ▸ | JUN | P05412 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665652 | 0.84 | BTK (0.41) | MAPK1MAPK8MAPK9MAPK10MAPK14 | |
| SCHEMBL21397349 | 0.84 | BTK (0.41) | MAPK1MAPK8MAPK9MAPK10MAPK14 | |
| SCHEMBL21397371 | 0.80 | MAPK1 (0.42) | MAPK1MAPK3GPR119MAPK8MAPK9 | |
| SCHEMBL21397410 | 0.76 | CDK7 (0.45) | — | |
| SCHEMBL16665651 | 0.76 | CDK7 (0.45) | — | |
| SCHEMBL21549476 | 0.72 | CDK7 (0.48) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL16665668 | 0.72 | CDK12 (0.53) | MAPK8MAPK9CDK2 | |
| SCHEMBL20416064 | 0.72 | CDK7 (0.42) | MAPK8MAPK9JUNCDK2MAPK10 | |
| SCHEMBL18047393 | 0.68 | CDK7 (0.66) | MAPK8MAPK9CDK2 | |
| SCHEMBL18047439 | 0.68 | CDK7 (0.66) | MAPK8MAPK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | MAPK1 538/4885MAPK3 537/4885GPR119 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.